“Deucravacitinib Long-term Efficacy Through 4 Years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program”, J of Skin, vol. 8, no. 6, p. s422, Nov. 2024, doi: 10.25251/skin.8.supp.422.